Aclaris Q3 2026: $204.6M Cash, Runway to 1H 2029, ATI-052 Pivots to EoE
ACRS sits 72% above its 52-week low of $2.1.
Summary
Aclaris reported Q3 2026 results with $204.6M in cash and runway into the first half of 2029, and said it will prioritize ATI-052 development in eosinophilic esophagitis. Bosakitug Phase 2 AD data and the modzatinib Phase 2b start are both expected in Q4 2026.
Key Events · Earnings and Guidance · ACRS
-
Q3 Loss Widens, Revenue Falls
Net loss was $18.5 million for Q3 2026 versus $14.6 million a year earlier, and the nine-month net loss reached $59.8 million. Total revenue fell to $1.5 million from $3.3 million, driven by a Sun Pharma sales milestone booked in the prior-year period.
-
Cash of $204.6M, Runway to 1H 2029
Cash, cash equivalents and marketable securities stood at $204.6 million on September 30, 2026, up from $151.4 million at December 31, 2025. Including net proceeds from the October offering, management expects funding through the first half of 2029.
-
ATI-052 Prioritized in EoE
Aclaris will initially pursue Phase 2b development of ATI-052 in eosinophilic esophagitis, with a second indication (likely AD or asthma) to be chosen shortly. This follows the positive Phase 1b proof-of-concept results announced October 27, 2026.
-
Two Readouts Due in Q4 2026
Top-line results from the 109-patient Phase 2 ADMIRATION trial of bosakitug in atopic dermatitis are expected in Q4 2026, and the modzatinib Phase 2b trial in lichen planus is expected to start in Q4 2026 with first site activation in November 2026.
Analysis · ACRS · Life Sciences
The quarter itself is unremarkable — revenue fell to $1.5M and the net loss widened to $18.5M — but the balance sheet is the story: $204.6M in cash after the October raise funds operations into the first half of 2029, removing any near-term financing need. Management also narrowed its capital allocation, choosing eosinophilic esophagitis as the first Phase 2b indication for ATI-052 rather than chasing AD and asthma simultaneously. Two readouts sit weeks away: bosakitug Phase 2 ADMIRATION top-line data and the modzatinib lichen planus Phase 2b start, both guided to the fourth quarter of 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRS was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $570.3M. The 52-week trading range was $2.10 to $6.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.